Uncategorized

City banks nearly $100M for next-gen RNAi drugs

Published

on

Co-founded by longtime Alnylam CEO John Maraganore, City has brought a clotting disorder drug into early human testing. An experimental therapy for Stargardt disease could soon follow.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version